FTC Suit Kills Sanofi/Maze Licensing Deal; Will It Doom The Pompe Candidate?

 
• By Nielsen Hobbs

Faced with a lawsuit asserting it had acquired an asset because it was a potential threat, Sanofi bows out of agreement to develop Maze’s GYS1 inhibitor. A test for FTC’s competition theory will be whether MZE001 eventually makes it to the market through other means.

Stop-sign-and-stop-light
The Sanofi/Maze deal will not be moving forward • Source: Shutterstock

The US Federal Trade Commission’s more muscular antitrust enforcement under the Biden administration notched another win on 11 December when Sanofi terminated its development agreement with Maze Therapeutics for the Pompe disease candidate MZE001.

FTC had authorized a lawsuit challenging Sanofi’s deal with Maze on grounds that it would “eliminate a nascent competitor poised to challenge Sanofi’s

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet